share_log

Intelligent Bio Solutions | 8-K: Current report

Intelligent Bio Solutions | 8-K: Current report

Intelligent Bio Solutions | 8-K:重大事件
美股SEC公告 ·  04/12 08:32

Moomoo AI 已提取核心信息

Intelligent Bio Solutions Inc., a medical technology company listed on Nasdaq under the symbol INBS, announced on April 11, 2024, the expansion of its intellectual property portfolio with the grant of a new European patent for its subsidiary, Intelligent Fingerprinting Limited. The patent, which has unitary effect, covers the DSR-Plus Cartridge Reader, a device that facilitates non-invasive, rapid drug screening through fingerprint sweat analysis. This technology is particularly useful in workplace and safety-critical environments. The European patent enables the company to enforce its rights in 17 European countries, marking a significant step in Intelligent Bio Solutions' strategy to expand its global presence and offer its advanced solutions to a wider market. The company's CEO, Harry Simeonidis, expressed enthusiasm for the expansion into the European market and the potential to enhance workplace safety and health. The DSR-Plus Cartridge Reader is noted for its efficiency, providing results in less than ten minutes, and is part of the company's broader aim to revolutionize portable testing across various applications.
Intelligent Bio Solutions Inc., a medical technology company listed on Nasdaq under the symbol INBS, announced on April 11, 2024, the expansion of its intellectual property portfolio with the grant of a new European patent for its subsidiary, Intelligent Fingerprinting Limited. The patent, which has unitary effect, covers the DSR-Plus Cartridge Reader, a device that facilitates non-invasive, rapid drug screening through fingerprint sweat analysis. This technology is particularly useful in workplace and safety-critical environments. The European patent enables the company to enforce its rights in 17 European countries, marking a significant step in Intelligent Bio Solutions' strategy to expand its global presence and offer its advanced solutions to a wider market. The company's CEO, Harry Simeonidis, expressed enthusiasm for the expansion into the European market and the potential to enhance workplace safety and health. The DSR-Plus Cartridge Reader is noted for its efficiency, providing results in less than ten minutes, and is part of the company's broader aim to revolutionize portable testing across various applications.
Intelligent Bio Solutions Inc. 是一家在纳斯达克上市的医疗技术公司,股票代码为INBS,该公司于2024年4月11日宣布扩大其知识产权组合,为其子公司智能指纹有限公司授予一项新的欧洲专利。该专利具有统一效力,涵盖了DSR-Plus墨盒读取器,该设备通过指纹汗液分析促进非侵入性的快速药物筛查。这项技术在工作场所和安全关键环境中特别有用。这项欧洲专利使该公司能够在17个欧洲国家行使其权利,这标志着Intelligent Bio Solutions扩大其全球影响力并为更广泛的市场提供先进解决方案的战略迈出了重要一步。该公司首席执行官哈里·西蒙尼迪斯对向欧洲市场的扩张以及提高工作场所安全与健康的潜力表示了热情。DSR-Plus 卡式读卡器以其效率著称,可在不到十分钟的时间内提供结果,这是该公司彻底改变各种应用的便携式测试的更广泛目标的一部分。
Intelligent Bio Solutions Inc. 是一家在纳斯达克上市的医疗技术公司,股票代码为INBS,该公司于2024年4月11日宣布扩大其知识产权组合,为其子公司智能指纹有限公司授予一项新的欧洲专利。该专利具有统一效力,涵盖了DSR-Plus墨盒读取器,该设备通过指纹汗液分析促进非侵入性的快速药物筛查。这项技术在工作场所和安全关键环境中特别有用。这项欧洲专利使该公司能够在17个欧洲国家行使其权利,这标志着Intelligent Bio Solutions扩大其全球影响力并为更广泛的市场提供先进解决方案的战略迈出了重要一步。该公司首席执行官哈里·西蒙尼迪斯对向欧洲市场的扩张以及提高工作场所安全与健康的潜力表示了热情。DSR-Plus 卡式读卡器以其效率著称,可在不到十分钟的时间内提供结果,这是该公司彻底改变各种应用的便携式测试的更广泛目标的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息